Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A Burgers, Armando Santoro, Susana Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P Van Meerbeeck, Anna K Nowak, George Blumenschein, Jonathan M Siegel, Linda Kasten, Karl Köchert, Annette O Walter, Barrett H Childs, Cem Elbi, Raffit Hassan, Dean A Fennell
BACKGROUND: Few treatment options exist for second-line treatment of malignant pleural mesothelioma. We aimed to assess the antibody-drug conjugate anetumab ravtansine versus vinorelbine in patients with unresectable locally advanced or metastatic disease overexpressing mesothelin who had progressed on first-line platinum-pemetrexed chemotherapy with or without bevacizumab. METHODS: In this phase 2, randomised, open-label study, done at 76 hospitals in 14 countries, we enrolled adults (aged ≥18 years) with unresectable locally advanced or metastatic malignant pleural mesothelioma, an Eastern Cooperative Oncology Group performance status of 0-1, and who had progressed on first-line platinum-pemetrexed chemotherapy with or without bevacizumab...
April 2022: Lancet Oncology